Thus, it is conceivable that the FASN benefits observed in early clinical trials for non-small-cell carcinoma, breast cancer, and sarcoma (see “The Lipid Environment and NAFLD-Related HCC”) may be partially due to inhibition of this autophosphorylation loop, which in turn dampens the YAP/TAZ oncogenic pathway. The gene discussed is FASN; the disease is sarcoma.